Skip to main content

Viking Therapeutics Inc (VKTX) Stock

Viking Therapeutics Inc Stock Details, Movements and Public Alerts

Stock Details

Viking Therapeutics Inc (VKTX), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $31.79. Over the past 52 weeks, it has ranged between $18.92 and $43.15. This places the current price at 73.7% of its 52-week high and 68.0% above its 52-week low. Recent trading volume was recorded at 682,192. The 14-day Relative Strength Index (RSI) stands at 56.17, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $32.30 by 1.58%. Similarly, it is above its 200-day moving average of $31.53 by 0.82%. The MACD histogram is 0.55, indicating bullish momentum (MACD Line: 0.49, Signal Line: -0.06). There are currently 2 active alerts set for VKTX by users.

52-Week Range

$43.15 - $18.92

-26.33% from high · +68.02% from low

Avg Daily Volume

3,159,792

20-day average

100-day avg: 3,500,214

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

PEG Ratio

-0.03

Potentially undervalued

Price to Book

6.12

EV/EBITDA

-71.64

EPS (TTM)

-$3.19

Beta

0.77

Less volatile than market

Q:How is VKTX valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is VKTX's risk profile compared to the market?
With a beta of 0.77, Viking Therapeutics Inc is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 6.12 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

0.00%

Operating Margin

0.00%

Return on Equity

-47.30%

Return on Assets

-30.30%

Revenue Growth (YoY)

0.00%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is VKTX's business model?
Profitability metrics are not available for this stock.
Q:What are VKTX's recent growth trends?
Growth data is not available for this stock.

Company Size & Market

Market Cap

$3.9B

Revenue (TTM)

$0

Revenue/Share (TTM)

$0.00

Shares Outstanding

115.55M

Book Value/Share

$5.57

Asset Type

Common Stock

Q:What is VKTX's market capitalization and position?
Viking Therapeutics Inc has a market capitalization of $3.9B, classifying it as a mid-cap stock ($2B-$10B). Mid-caps often represent companies in their growth phase, offering higher growth potential than large-caps but with more stability than small-caps. They can be attractive takeover targets and may become tomorrow's large-caps. With 115.55M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does VKTX's price compare to its book value?
Viking Therapeutics Inc's book value per share is $5.57, while the current stock price is $31.79, resulting in a price-to-book (P/B) ratio of 5.71. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$92.72

191.66% upside potential

Analyst Recommendations

Strong Buy

5

Buy

12

Hold

1

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for VKTX?
18 analysts cover VKTX with 94% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $92.72 implies 191.7% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on VKTX?
Current analyst recommendations:5 Strong Buy, 12 Buy, 1 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Mar 3, 2026, 02:04 AM

Technical Indicators

RSI (14-day)

56.17

Neutral

50-Day Moving Average

$32.30

-1.58% below MA-50

200-Day Moving Average

$31.53

0.82% above MA-200

MACD Line

0.49

MACD Signal

-0.06

MACD Histogram

0.55

Bullish

Q:What does VKTX's RSI value tell investors?
The RSI (Relative Strength Index) for VKTX is currently 56.17, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this shows mixed signals requiring careful analysis.
Q:How should traders interpret VKTX's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.49 above the signal line at -0.06, with histogram at 0.55. This bullish crossover suggests upward momentum is building. The 50-day MA ($32.30) is above the 200-day MA ($31.53), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently between the MAs, suggesting transition.

Indicators last updated: Mar 3, 2026, 09:40 AM

Active Alerts

Alert Condition
Price increases by
Threshold
15%
Created
Feb 26, 2026, 05:30 PM
Alert Condition
Earnings Announcement
Threshold
3 days
Created
Jan 23, 2026, 05:23 PM

Stay Ahead of the Market with Viking Therapeutics Inc Alerts

Set up price alerts for Viking Therapeutics Inc and get notified instantly when the price hits your target. Never miss an important price movement again.